Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic

Objectives: Approximately 60% of lung adenocarcinomas (LAs) carry mutations that can guide treatment with tyrosine-kinase inhibitors (TKI) and other targeted therapies. Data on activating mutations in EGFR and other tyrosine-kinase receptor (TKR) genes in highly admixed populations, such as that of...

Descripción completa

Detalles Bibliográficos
Autores principales: Freitas, Helano C., Torrezan, Giovana Tardin, da Cunha, Isabela Werneck, Macedo, Mariana Petaccia, Karen de Sá, Vanessa, Corassa, Marcelo, Ferreira, Elisa Napolitano e, Saito, Augusto Obuti, Dal Molin, Graziela Zibetti, Cordeiro de Lima, Vladmir C., Carraro, Dirce Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343968/
https://www.ncbi.nlm.nih.gov/pubmed/32714871
http://dx.doi.org/10.3389/fonc.2020.01068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343968/
https://www.ncbi.nlm.nih.gov/pubmed/32714871
http://dx.doi.org/10.3389/fonc.2020.01068

Ejemplares similares